Systemic lupus erythematosus (SLE)
Namrata Singh, MD, MSc
University of Washington, United States
Disclosure: I have no relevant financial relationship(s) with ineligible companies to disclose.
Session Overview: Recent clinical trials have enriched the treatment landscape of lupus nephritis (LN), and this provides hope for the role of novel agents in managing LN. With trials supporting the use of belimumab and voclosporin in LN, the question remains about which agent to use first. In this year's Great Debate, presenters will debate this key question: "Enhancing lupus nephritis therapy: is the next step belimumab or voclosporin"?
Speaker: Michelle A. Petri, MD, MPH – Johns Hopkins University School of Medicine
Speaker: Brad H. Rovin, MD – The Ohio State University
Q&A Moderator: Namrata Singh, MD, MSc – University of Washington
Q&A Presenter: Michelle A. Petri, MD, MPH – Johns Hopkins University School of Medicine
Q&A Presenter: Brad H. Rovin, MD – The Ohio State University